CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Peanut OIT +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00597675
NCT00597675Phase 2Completed
CompareCT.gov

Oral Immunotherapy for Peanut Allergy (2nd Generation PMIT Collaboration With Arkansas Children's)

University of North Carolina, Chapel Hill·interventional·Posted Jan 18, 2008·Updated Mar 27, 2018

In Brief

A Phase 2 clinical trial evaluating Peanut OIT and Placebo for Food Hypersensitivity. Completed, enrolled 10 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine if mucosal peanut immunotherapy will make subjects who have peanut allergy less allergic and induce changes in their immune system.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFood Hypersensitivity
CountriesUnited States
CollaboratorsUniversity of Arkansas

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 18, 2008
Enrollment StartMar 1, 2007
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 18.5 years ago

Interventions

Peanut OITbiological

Defatted peanut flour ingested daily as oral mucosal immunotherapy

Placebobiological

Oat flour matched by weight and consistency that is ingested daily as a placebo